Long-Term Benefits of Anavex 2-73 in Parkinson’s Disease
Anavex Life Sciences has announced promising long-term data for its investigational therapy, Anavex 2-73, in the treatment of Parkinson’s disease dementia. The extension of a Phase 2 trial demonstrated that patients who received Anavex 2-73 experienced a reduction in the severity of their symptoms, contrasting sharply with the symptom progression observed during a drug hiatus. […]